Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD

1.24  +0.06 (+5.08%)

After market: 1.24 0 (0%)

Fundamental Rating

2

LXRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative. LXRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LXRX had negative earnings in the past year.
LXRX had a negative operating cash flow in the past year.
LXRX had negative earnings in each of the past 5 years.
LXRX had a negative operating cash flow in each of the past 5 years.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

With a Return On Assets value of -59.56%, LXRX perfoms like the industry average, outperforming 41.45% of the companies in the same industry.
With a Return On Equity value of -144.11%, LXRX is not doing good in the industry: 62.18% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -59.56%
ROE -144.11%
ROIC N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

LXRX's Gross Margin of 98.03% is amongst the best of the industry. LXRX outperforms 98.00% of its industry peers.
LXRX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LXRX has more shares outstanding
Compared to 5 years ago, LXRX has more shares outstanding
The debt/assets ratio for LXRX has been reduced compared to a year ago.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -9.22, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
LXRX's Altman-Z score of -9.22 is on the low side compared to the rest of the industry. LXRX is outperformed by 71.64% of its industry peers.
LXRX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
LXRX has a Debt to Equity ratio of 0.48. This is in the lower half of the industry: LXRX underperforms 74.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -9.22
ROIC/WACCN/A
WACC10.69%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

LXRX has a Current Ratio of 2.22. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a Current ratio of 2.22. This is in the lower half of the industry: LXRX underperforms 73.82% of its industry peers.
A Quick Ratio of 2.22 indicates that LXRX has no problem at all paying its short term obligations.
LXRX's Quick ratio of 2.22 is on the low side compared to the rest of the industry. LXRX is outperformed by 71.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.22
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.69% over the past year.
LXRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 2481.48%.
LXRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -37.35% yearly.
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.88%
Revenue 1Y (TTM)2481.48%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%1652.64%

3.2 Future

LXRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.78% yearly.
The Revenue is expected to grow by 73.16% on average over the next years. This is a very strong growth
EPS Next Y37.94%
EPS Next 2Y19.69%
EPS Next 3Y18.4%
EPS Next 5Y12.78%
Revenue Next Year24.27%
Revenue Next 2Y5.84%
Revenue Next 3Y47.03%
Revenue Next 5Y73.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

LXRX's earnings are expected to grow with 18.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.69%
EPS Next 3Y18.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (8/15/2025, 5:56:29 PM)

After market: 1.24 0 (0%)

1.24

+0.06 (+5.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners76.48%
Inst Owner Change0.14%
Ins Owners0.86%
Ins Owner Change0.4%
Market Cap450.34M
Analysts80
Price Target2.63 (112.1%)
Short Float %8.14%
Short Ratio6.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.16%
Min EPS beat(2)29.61%
Max EPS beat(2)30.7%
EPS beat(4)3
Avg EPS beat(4)16.18%
Min EPS beat(4)-7.28%
Max EPS beat(4)30.7%
EPS beat(8)6
Avg EPS beat(8)6.98%
EPS beat(12)9
Avg EPS beat(12)4.55%
EPS beat(16)13
Avg EPS beat(16)6.23%
Revenue beat(2)1
Avg Revenue beat(2)144.65%
Min Revenue beat(2)-12.42%
Max Revenue beat(2)301.73%
Revenue beat(4)1
Avg Revenue beat(4)51.23%
Min Revenue beat(4)-42.95%
Max Revenue beat(4)301.73%
Revenue beat(8)2
Avg Revenue beat(8)51.66%
Revenue beat(12)2
Avg Revenue beat(12)6.99%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)223.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)32.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.43
P/FCF N/A
P/OCF N/A
P/B 3.66
P/tB 5.74
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.09
BVpS0.34
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.56%
ROE -144.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.03%
FCFM N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.22
Altman-Z -9.22
F-Score5
WACC10.69%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.88%
EPS Next Y37.94%
EPS Next 2Y19.69%
EPS Next 3Y18.4%
EPS Next 5Y12.78%
Revenue 1Y (TTM)2481.48%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%1652.64%
Revenue Next Year24.27%
Revenue Next 2Y5.84%
Revenue Next 3Y47.03%
Revenue Next 5Y73.16%
EBIT growth 1Y4.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-71.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.43%
OCF growth 3YN/A
OCF growth 5YN/A